Long-term survival of favorable-risk patients with metastatic renal cell carcinoma treated with second-line axitinib in a multicenter phase II study.

被引：0
|
作者：
Tsimafeyeu, Ilya [1 ]
Borisov, Pavel S. [2 ]
Semenov, Andrey [3 ]
Leonenkov, Roman [4 ]
Novikova, Olga [5 ]
Gamayunov, Sergey [6 ]
Mikhailova, Nadezhda [7 ]
Bondarenko, Anastasia [8 ]
Abdelgafur, Ahmed [6 ]
机构：
[1] Kidney Canc Res Bur, Moscow, Russia
[2] City Clin Oncol Ctr, St Petersburg, Russia
[3] Ivanovo Canc Ctr, Ivanovo, Russia
[4] St Petersburg City Canc Ctr, St Petersburg, Russia
[5] Khabarovsk Reg Canc Ctr, Khabarovsk, Russia
[6] Republican Clin Oncol Ctr, Cheboksary, Russia
[7] Republican Clin Oncol Ctr, Kazan, Russia
[8] IM Sechenov First Moscow State Med Univ, Moscow, Russia
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 06期
关键词：
D O I：
10.1200/JCO.2021.39.6_suppl.332
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
332
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Phase 2 Multicenter Single-Arm Study of Second-Line Axitinib in Favorable Risk Patients with Metastatic Renal Cell Carcinoma: FavorAx
    Tsimafeyeu, Ilya
    Borisov, Pavel
    Abdelgafur, Ahmed
    Leonenkov, Roman
    Novikova, Olga
    Guseva, Irina
    Demchenkova, Marina
    Mikhailova, Nadezhda
    Semenov, Andrey
    Yurmazov, Zakhar
    Sivunova, Irina
    Ramazanova, Madina
    Gamayunov, Sergey
    Kosov, Dmitry
    Bratslavsky, Gennady
    TARGETED ONCOLOGY, 2019, 14 (01) : 33 - 38
  • [2] Phase 2 Multicenter Single-Arm Study of Second-Line Axitinib in Favorable Risk Patients with Metastatic Renal Cell Carcinoma: FavorAx
    Ilya Tsimafeyeu
    Pavel Borisov
    Ahmed Abdelgafur
    Roman Leonenkov
    Olga Novikova
    Irina Guseva
    Marina Demchenkova
    Nadezhda Mikhailova
    Andrey Semenov
    Zakhar Yurmazov
    Irina Sivunova
    Madina Ramazanova
    Sergey Gamayunov
    Dmitry Kosov
    Gennady Bratslavsky
    Targeted Oncology, 2019, 14 : 33 - 38
  • [3] Second-line treatment with axitinib plus toripalimab in metastatic renal cell carcinoma: a retrospective multicenter study
    Huang, Jiwei
    Shi, Guohai
    Wang, Yueming
    Wang, Ping
    Zhang, Jin
    Kong, Wen
    Huang, Yiran
    Wang, Shuo
    Xue, Wei
    FUTURE ONCOLOGY, 2022, 18 (12) : 1461 - 1471
  • [4] Phase II randomized study of dalantercept in combination with axitinib compared to axitinib alone as second-line treatment in patients with metastatic renal cell carcinoma.
    Atkins, Michael B.
    Bhatt, Rupal Satish
    Voss, Martin Henner
    Rini, Brian I.
    Jonasch, Eric
    Plimack, Elizabeth R.
    Alter, Robert
    Barger, Rachel
    Wilson, Dawn
    McClure, Ty
    Kumar, Ravi
    Attie, Kenneth M.
    Sherman, Matthew L.
    Pandya, Shuchi Sumant
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [5] Long-Term Safety With Axitinib in Previously Treated Patients With Metastatic Renal Cell Carcinoma
    Rini, Brian I.
    Escudier, Bernard
    Hariharan, Subramanian
    Roberts, W. Gregory
    Tarazi, Jamal
    Rosbrook, Brad
    Askeroya, Zena
    DeAnnuntis, Liza L.
    Motzer, Robert J.
    CLINICAL GENITOURINARY CANCER, 2015, 13 (06) : 540 - 547
  • [6] Axitinib in metastatic renal cell carcinoma: beyond the second-line setting
    Umeyama, Yoshiko
    Shibasaki, Yoshiyuki
    Akaza, Hideyuki
    FUTURE ONCOLOGY, 2017, 13 (21) : 1839 - 1852
  • [7] Cabopoint: a phase II study of second-line cabozantinib in patients with metastatic renal cell carcinoma (RCC)
    Ivanyi, P.
    Albiges, L.
    Schmidinger, M.
    Taguieva-Pioger, N.
    Perol, D.
    Gruenwald, V
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 274 - 274
  • [8] CaboPoint: A phase II study of second-line cabozantinib in patients with metastatic renal cell carcinoma (RCC)
    Albiges, L.
    Schmidinger, M.
    Taguieva-Pioger, N.
    Perol, D.
    Gruenwald, V.
    ANNALS OF ONCOLOGY, 2020, 31 : S608 - S609
  • [9] CaboPoint: a Phase II study of cabozantinib as second-line treatment in patients with metastatic renal cell carcinoma
    Albiges, Laurence
    Schmidinger, Manuela
    Taguieva-Pioger, Naila
    Perol, David
    Grunwald, Viktor
    Guemas, Eric
    FUTURE ONCOLOGY, 2022, 18 (08) : 915 - 925
  • [10] Efficacy and safety of second-line axitinib in octogenarians with metastatic renal cell carcinoma
    Nakai, Yasutomo
    Takeuchi, Ario
    Osawa, Takahiro
    Kojima, Takahiro
    Hara, Tomohiko
    Sugimoto, Mikio
    Eto, Masatoshi
    Minami, Keita
    Ueda, Kosuke
    Ozawa, Michinobu
    Uemura, Motohide
    Miyauchi, Yasuyuki
    Ohba, Kojiro
    Kashiwagi, Akira
    Murakami, Masaya
    Sazuka, Tomokazu
    Yasumoto, Hiroaki
    Morizane, Shuichi
    Kawasaki, Yoshihide
    Morooka, Daichi
    Shimazui, Toru
    Yamamoto, Yoshiaki
    Nakagomi, Hiroshi
    Tomida, Ryotaro
    Ito, Yoichi M.
    Murai, Sachiyo
    Kitamura, Hiroshi
    Nishiyama, Hiroyuki
    Shinohara, Nobuo
    JOURNAL OF GERIATRIC ONCOLOGY, 2021, 12 (05) : 834 - 837
12345